Valdivieso M, Umsawasdi T, Spitzer G, Chiuten D F, Booser D J, Dhingra H M, Bodey G P
Am J Clin Oncol. 1984 Jun;7(3):241-4. doi: 10.1097/00000421-198406000-00008.
A phase II clinical study of dihydroxyanthracenedione ( DHAD ) was conducted in 50 patients with advanced lung cancers. DHAD was administered intravenously on a 5-day schedule repeated every 4 weeks. Most patients had adenocarcinoma (46%), and had received previous chemotherapy (66%) and radiation therapy (50%). Among 41 evaluable patients, there were four partial remissions, eight disease stabilizations and 29 disease progressions. Remissions were more common among previously untreated patients (20% vs. 4%), particularly in patients with adenocarcinoma and large cell carcinomas of whom 3/10 (30%) responded. Responses lasted 9+, 9, 7, and 3 months, respectively. Cardiac toxicity was not observed. Other toxicities were tolerable. DHAD is a potentially useful agent for the therapy of adenocarcinoma and large cell lung cancers.
对50例晚期肺癌患者进行了二羟基蒽二酮（DHAD）的II期临床研究。DHAD采用静脉给药，每5天为一个疗程，每4周重复一次。大多数患者为腺癌（46%），且之前接受过化疗（66%）和放疗（50%）。在41例可评估患者中，有4例部分缓解，8例病情稳定，29例病情进展。缓解在先前未接受治疗的患者中更为常见（20%对4%），特别是腺癌和大细胞癌患者，其中3/10（30%）有反应。缓解分别持续9个月以上、9个月、7个月和3个月。未观察到心脏毒性。其他毒性是可耐受的。DHAD是治疗腺癌和大细胞肺癌的一种潜在有用药物。
